No Data
Baili Tianheng (688506.SH): The combination therapy of BL-M11D1 (CD33-ADC) for newly diagnosed acute myeloid leukemia has received the drug clinical trial approval notice.
On April 22, Gelonghui reported that Bailitianheng (688506.SH) announced it recently received the "Notice of Approval for Pharmaceutical Clinical Trials" formally issued by the National Medical Products Administration (NMPA), approving the clinical trial of its independently developed innovative biological drug, injectable BL-M11D1 (CD33-ADC) in combination therapy. BL-M11D1 is a targeted CD33 ADC drug derived from the same technology platform as BL-B01D1, sharing the same "linker + toxin" platform with BL-B01D1. As of now, apart from the newly approved clinical trial,
Bailitianheng (688506.SH): 10.8207 million restricted shares will be released on April 28.
Gelonghui, April 18th丨Baili Tianheng (688506.SH) announced that the total number of Stocks listed for circulation this time is 10.8207 million shares. The Stocks listing circulation date is April 28, 2025.
Express News | Biokin Pharmaceutical Lock-up Period for 2.7% Stake to End, Shares to Start Trading on April 28
Estimating The Intrinsic Value Of Sichuan Biokin Pharmaceutical Co.,Ltd. (SHSE:688506)
Biokin Pharmaceutical Gets Nod to Trial Tumor Drug
Bailitianheng (688506.SH): BL-B01D1 (EGFR×HER3 dual antibody ADC) has completed the enrollment of the first subject in the Phase III clinical trial for locally advanced or metastatic urothelial carcinoma.
On April 8, Gelonghui reported that Bai Li Tianheng (688506.SH) announced that the Phase III clinical trial for the self-developed innovative biopharmaceutical injection BL-B01D1 (EGFR×HER3 dual antibody ADC) for patients with unresectable locally advanced or metastatic urothelial carcinoma who have failed prior platinum-based chemotherapy and PD-1/PD-L1 inhibitors has recently completed the enrollment of the first subject. This is the ninth registered clinical study for this product to enter Phase III. BL-B01D1 is a Global first-in-class, new Concept.
